{"disease":{"id":"african-trypanosomiasis","name":"African trypanosomiasis","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":3,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"fexinidazole","indication_name":"Human African Trypanosomiasis (HAT)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fexinidazole","generic_name":"FEXINIDAZOLE","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"","drug_class":"Nitroimidazole Antimicrobial [EPC]","quality_score":49,"revenue":null,"mechanism":"Fexinidazole works by releasing free radicals that damage the DNA of Trypanosoma brucei gambiense, ultimately killing the parasite."},{"drug_id":"fexinidazole","indication_name":"Human African trypanosomiasis (HAT) due to Trypanosoma brucei gambiense","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fexinidazole","generic_name":"FEXINIDAZOLE","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"","drug_class":"Nitroimidazole Antimicrobial [EPC]","quality_score":49,"revenue":null,"mechanism":"Fexinidazole works by releasing free radicals that damage the DNA of Trypanosoma brucei gambiense, ultimately killing the parasite."},{"drug_id":"pentamidine","indication_name":"African trypanosomiasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pentam","generic_name":"PENTAMIDINE","company_name":"Fresenius Kabi","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M4","drug_class":"Antiprotozoal","quality_score":80,"revenue":null,"mechanism":"Pentamidine works by interfering with the reproduction of certain parasites, such as Pneumocystis jiroveci."},{"drug_id":"eflornithine","indication_name":"African trypanosomiasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vaniqa","generic_name":"EFLORNITHINE","company_name":"","drug_phase":"marketed","molecular_target":"Ornithine decarboxylase (ODC)","drug_class":"Antiprotozoal","quality_score":75,"revenue":null,"mechanism":"Eflornithine inhibits ornithine decarboxylase, reducing polyamine synthesis and affecting cancer cell growth and metabolism."},{"drug_id":"melarsoprol","indication_name":"African trypanosomiasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Arsobal","generic_name":"MELARSOPROL","company_name":"","drug_phase":"phase_3","molecular_target":"","drug_class":"melarsoprol","quality_score":null,"revenue":null,"mechanism":"Arsobal works by inhibiting the enzyme dihydrofolate reductase in the parasite, disrupting its ability to synthesize DNA and ultimately leading to its death."}],"pipeline":[],"offLabel":[],"totalMarketed":5,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04099628","title":"Diagnostic Tools for Human African Trypanosomiasis Elimination and Clinical Trials: WP3 Post Elimination Monitoring","phase":"NA","overall_status":"COMPLETED","enrollment_count":13747,"lead_sponsor_name":"Institut de Recherche pour le Developpement","has_results":false},{"nct_id":"NCT03356665","title":"Diagnostic Tools for Human African Trypanosomiasis Elimination and Clinical Trials: WP2 Passive Case Detection","phase":"NA","overall_status":"COMPLETED","enrollment_count":10700,"lead_sponsor_name":"Institut de Recherche pour le Developpement","has_results":false},{"nct_id":"NCT06356974","title":"Stop Transmission of Gambiense Human African Trypanosomiasis (STROgHAT)","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":2500,"lead_sponsor_name":"Drugs for Neglected Diseases","has_results":false},{"nct_id":"NCT05637632","title":"Assessment of Recombinant HAT-RDT Specificity","phase":"","overall_status":"COMPLETED","enrollment_count":1504,"lead_sponsor_name":"Institute of Tropical Medicine, Belgium","has_results":false},{"nct_id":"NCT05466630","title":"Prospective Evaluation of the Specificity of Serological Tests for Human African Trypanosomiasis","phase":"NA","overall_status":"COMPLETED","enrollment_count":1095,"lead_sponsor_name":"Institut de Recherche pour le Developpement","has_results":false},{"nct_id":"NCT02169557","title":"Efficacy and Safety of Fexinidazole in Patients With Stage 1 or Early Stage 2 Human African Trypanosomiasis (HAT) Due to T.b. Gambiense: a Prospective, Multicentre, Open-label Cohort Study, plug-in to the Pivotal Study","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":230,"lead_sponsor_name":"Drugs for Neglected Diseases","has_results":false},{"nct_id":"NCT03087955","title":"Efficacy and Safety of Acoziborole (SCYX-7158) in Patients With Human African Trypanosomiasis Due to T.b. Gambiense","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":208,"lead_sponsor_name":"Drugs for Neglected Diseases","has_results":true},{"nct_id":"NCT03025789","title":"Fexinidazole in Human African Trypanosomiasis Due to T.b. Gambiense at Any Stage","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":174,"lead_sponsor_name":"Drugs for Neglected Diseases","has_results":true},{"nct_id":"NCT02184689","title":"Efficacy and Safety of Fexinidazole in Children at Least 6 Years Old and Weighing Over 20 kg With Human African Trypanosomiasis (HAT) Due to T.b. Gambiense: a Prospective, Multicentre, Open Study, plug-in to the Pivotal Study","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":125,"lead_sponsor_name":"Drugs for Neglected Diseases","has_results":false},{"nct_id":"NCT03112655","title":"Diagnostic Tools for Human African Trypanosomiasis Elimination and Clinical Trials: Early Test-of-cure","phase":"NA","overall_status":"COMPLETED","enrollment_count":88,"lead_sponsor_name":"Institut de Recherche pour le Developpement","has_results":false},{"nct_id":"NCT03394976","title":"Prospective Evaluation of an RDT to Screen for Gambiense HAT and Diagnose P. Falciparum Malaria","phase":"","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Foundation for Innovative New Diagnostics, Switzerland","has_results":false}],"total":11},"guidelines":[],"source":"Drug Landscape verified database"}